Anti-HER2 induced myeloid cell alterations correspond with increasing vascular maturation in a murine model of HER2+ breast cancer

BACKGROUND: Therapy targeted to the human epidermal growth factor receptor type 2 (HER2) is used in combination with cytotoxic therapy in treatment of HER2+ breast cancer. Trastuzumab, a monoclonal antibody that targets HER2, has been shown pre-clinically to induce vascular changes that can increase...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:BMC Cancer
Main Authors: Bloom, Meghan J., Jarrett, Angela M., Triplett, Todd A., Syed, Anum K., Davis, Tessa, Yankeelov, Thomas E., Sorace, Anna G.
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2020
Teme:
Research Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7189470/
https://ncbi.nlm.nih.gov/pubmed/32345237
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-020-06868-4
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki